Ceftazidime and Blindness - a phase IV clinical study of FDA data

Summary:

Blindness is reported as a side effect among people who take Ceftazidime (ceftazidime), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Vancomycin, and have Panophthalmitis.

The phase IV clinical study analyzes which people have Blindness when taking Ceftazidime. It is created by eHealthMe based on reports of 10,307 people who have side effects when taking Ceftazidime from the FDA, and is updated regularly.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

What is Blindness?

Blindness is found to be associated with 1,509 drugs and 1,986 conditions by eHealthMe. Check the latest studies of Blindness.

On Jul, 19, 2026

10,307 people reported to have side effects when taking Ceftazidime.
Among them, 25 people (0.24%) have Blindness.

Among these 25 people:

How long have people been on Ceftazidime when they have Blindness? *

What is the gender of people who have Blindness when taking Ceftazidime? *

female: 43.48 %
male: 56.52 %

What is the age of people who have Blindness when taking Ceftazidime? *

What are other drugs people take besides Ceftazidime? *

Vancomycin: 21 people, 84.00%
Cytarabine: 5 people, 20.00%
Heparin: 5 people, 20.00%
Acetaminophen: 4 people, 16.00%
Fludarabine Phosphate: 3 people, 12.00%
Eylea: 3 people, 12.00%
Prednisolone: 3 people, 12.00%
Dexamethasone Sodium Phosphate: 3 people, 12.00%
Moxifloxacin: 3 people, 12.00%
Vabysmo: 3 people, 12.00%

What are other side effects people have besides Blindness? *

Endophthalmitis (inflammation of the internal coats of the eye): 9 people, 36.00%
Drug Ineffective: 5 people, 20.00%
Eye Pain: 4 people, 16.00%
Necrosis (the death of body tissue): 3 people, 12.00%
Optic Nerve Disorder (disease of optic nerve): 3 people, 12.00%
Retinal Detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue): 3 people, 12.00%
Petit Mal Epilepsy (absence seizure): 2 people, 8.00%
Vitreous Floaters (spots before the eyes): 2 people, 8.00%
Corneal Oedema (corneal swelling): 2 people, 8.00%
Electroencephalogram Abnormal: 2 people, 8.00%

What are the existing conditions these people have? *

Panophthalmitis (inflammation of all the eye structures or tissues): 4 people, 16.00%
Endophthalmitis (inflammation of the internal coats of the eye): 3 people, 12.00%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 3 people, 12.00%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 2 people, 8.00%
Age-Related Macular Degeneration: 2 people, 8.00%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 8.00%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 1 person, 4.00%
Necrotising Retinitis (life threatening infection of retina): 1 person, 4.00%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 4.00%
Macular Fibrosis (a thin sheet of scar tissue forms on top of the macula, in response to damage or injury): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and have Blindness?

- Check whether Blindness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftazidime:

Ceftazidime (10,327 reports)

Blindness treatments and more:

Blindness (45,948 reports)

Browse all side effects of Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blindness:

Blindness (1,509 drugs)

Browse all the conditions that are associated with Blindness:

Blindness (1,986 conditions)

Related publications that referenced our studies

Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .
Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime (the active ingredients of Ceftazidime) and Ceftazidime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.